The Americans with Disabilities Act ensures that people living with disabilities receive reasonable accommodations at work. That law also applies to students attending most colleges and universities. And the ADA doesn't limit itself to physical disabilities. It's often applied to invisible disabilities, as well.
This week, Britt Neff, the Access Specialist at the University of Washington School of Law, joins me to explain all the ways the accommodation process can work for college students living with MS.
We'll also tell you about PTD802, an oral remyelination therapy that's just been given a green light from the FDA to begin human clinical trials
We're sharing evidence from an important study that should make you feel more confident about getting those MMR (measles, mumps, rubella) and chickenpox vaccines.
You'll learn what researchers at the Cleveland Clinic discovered when they asked the question, “Can someone living with MS over the age of 60 discontinue their disease-modifying therapy?“
And we're sharing the details about an AI application that can predict — with 90% accuracy — whether someone with MS is at risk of experiencing cognitive decline over the next few years.
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: Understanding “reasonable accommodation” at college :22
FDA approves oral remyelination therapy PTD802 for Phase 1 clinical trial 1:07
Study results: MMR (measles, mumps, rubella) and chickenpox vaccines are shown to be safe for people with MS 4:52
Study results: Is it safe for someone living with MS over 60 to discontinue their DMT? 7:34
Study results: AI predicts future cognitive changes among people with MS with 90% accuracy 10:45
Britt Neff explains the many types of accommodation available to college students with MS 15:01
Share this episode 28:24
Next week 28:44
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/462
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com
Pheno Therapeutics
https://phenotherapeutics.com
STUDY: Live Attenuated MMR and Varicella Vaccinations and Multiple Sclerosis Activity
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2849165
STUDY: Long-Term Follow-Up of Patients with Multiple Sclerosis Over Age 60: Comparing Clinical and Radiological Outcomes in Disease-Modifying Therapy Continuers and Discontinuers
https://journals.sagepub.com/doi/full/10.1177/20552173261448005
STUDY: Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data
https://onlinelibrary.wiley.com/doi/10.1111/ene.70568
JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms
REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review
Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 462
Guest: Britt Neff
Episode 461: A New Disease-Modifying Therapy Has Been Submitted for FDA Approval with Dr. Jiwon Oh
A short while ago, we shared very positive results from the Phase 3 clinical trials for fenebrutinib in both relapsing-remitting and primary progressive MS. Those results have been submitted to the FDA for approval.
This week, Dr. Jiwon Oh, the principal investigator in one of the Phase 3 trials for fenebrutinib, walks us through these positive results and explains what makes fenebrutinib a different kind of disease-modifying therapy and who might benefit most from it.
We're also talking about the European approval of Cenrifki (Tolebrutinib) to treat nonrelapsing secondary progressive MS, and we'll share our perspective on why the FDA should have — and should still — approve this DMT in the U.S.
We'll tell you about two studies funded by the National MS Society that will focus on identifying links between menopause and MS.
We'll share some sobering news about healthcare affordability in America.
And we'll share some good news from the U.S. House Appropriations Committee, along with an opportunity for you to spend just 5 minutes doing some important advocacy work.
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: Fenebrutinib has been submitted to the FDA for approval :22
Cenrifki (Tolebrutinib) approved in Europe for Nonrelapsing Secondary Progressive MS 1:09
National MS Society funds two studies to identify links between menopause and MS 4:19
Healthcare has become unaffordable for the majority of Americans 8:23
The U.S. House Appropriations Committee has approved $20 million in funding for the MS Research Program 11:57
Dr. Jiwon Oh explains why Fenebrutinib is a different kind of disease-modifying therapy, and who may benefit from it 15:36
Share this episode 32:22
Next week 32:43
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/461
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com
PHASE 3 CLINICAL TRIAL: Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
https://www.nejm.org/doi/abs/10.1056/NEJMoa2415988
VIDEO: Principal Investigator Dr. Robert Fox Discusses the Phase 3 clinical trial for Tolebrutinib in Nonrelapsing Secondary Progressive MS
https://www.youtube.com/watch?v=tJQ93qdlXrU
GALLUP POLL: U.S. Adults' Ability to Afford Healthcare at a Five-Year Low
https://news.gallup.com/poll/710942/adults-ability-afford-healthcare-five-year-low.aspx
JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms
REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review
Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 461
Guest: Dr. Jiwon Oh